dc.contributor.author |
Lanzafame, Massimiliano
|
|
dc.contributor.author |
Vento, Sandro
|
|
dc.creator |
Massimiliano, Lanzafame |
|
dc.date.accessioned |
2017-12-15T03:57:32Z |
|
dc.date.available |
2017-12-15T03:57:32Z |
|
dc.date.issued |
2016-05-01 |
|
dc.identifier |
DOI:10.1016/j.jctube.2016.03.002 |
|
dc.identifier.citation |
Massimiliano Lanzafame, Sandro Vento, Tuberculosis-immune reconstitution inflammatory syndrome, In Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Volume 3, 2016, Pages 6-9 |
en_US |
dc.identifier.issn |
24055794 |
|
dc.identifier.uri |
https://www.sciencedirect.com/science/article/pii/S2405579415300097 |
|
dc.identifier.uri |
http://nur.nu.edu.kz/handle/123456789/2920 |
|
dc.description.abstract |
Abstract Tuberculosis-immune reconstitution inflammatory syndrome is an excessive immune response against Mycobacterium tuberculosis that may occur in either HIV-infected or uninfected patients, during or after completion of anti-TB therapy. In HIV-infected patients it occurs after initiation of antiretroviral therapy independently from an effective suppression of HIV viremia. There are two forms of IRIS: paradoxical or unmasking. Paradoxical IRIS is characterized by recurrent, new, or worsening symptoms of a treated case. Unmasking IRIS is an antiretroviral-associated inflammatory manifestation of a subclinical infection with a hastened presentation. The pathogenesis is incompletely understood and the epidemiology partially described. No specific tests can establish or rule out the diagnosis. Treatment is based on the use of anti-tuberculosis drugs sometime with adjunctive corticosteroids. Mortality is generally low. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
en_US |
dc.relation.ispartof |
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
|
dc.subject |
Tuberculosis |
en_US |
dc.subject |
IRIS |
en_US |
dc.subject |
Immune reconstitution |
en_US |
dc.subject |
HIV |
en_US |
dc.subject |
Antiretrovirals |
en_US |
dc.title |
Tuberculosis-immune reconstitution inflammatory syndrome |
en_US |
dc.type |
Article |
en_US |
dc.rights.license |
© 2016 Published by Elsevier Ltd. |
|
elsevier.identifier.doi |
10.1016/j.jctube.2016.03.002 |
|
elsevier.identifier.eid |
1-s2.0-S2405579415300097 |
|
elsevier.identifier.pii |
S2405-5794(15)30009-7 |
|
elsevier.identifier.scopusid |
84961595319 |
|
elsevier.volume |
3 |
|
elsevier.coverdate |
2016-05-01 |
|
elsevier.coverdisplaydate |
May 2016 |
|
elsevier.startingpage |
6 |
|
elsevier.endingpage |
9 |
|
elsevier.openaccess |
1 |
|
elsevier.openaccessarticle |
true |
|
elsevier.openarchivearticle |
false |
|
elsevier.openaccessuserlicense |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
elsevier.teaser |
Tuberculosis-immune reconstitution inflammatory syndrome is an excessive immune response against Mycobacterium tuberculosis that may occur in either HIV-infected or uninfected patients, during or after... |
|
elsevier.aggregationtype |
Journal |
|
workflow.import.source |
science |
|